<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941808</url>
  </required_header>
  <id_info>
    <org_study_id>19-PP-01</org_study_id>
    <nct_id>NCT03941808</nct_id>
  </id_info>
  <brief_title>Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo.</brief_title>
  <acronym>Vitisod</acronym>
  <official_title>Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo. A Randomized Double Blind Placebo Controlled Monocentric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of the oxidative stress in vitiligo is supported by many studies but robust data are
      lacking concerning their interest as therapeutic agents. The objective of the study is to
      compare the association of GLISODIN (a gastro-protected superoxide dismutase) and Nb-UVB to
      Nb-UVB and placebo for treating vitiligo.

      Adult patients with non-segmental vitiligo affecting more than 5% of body surface area will
      be included.

      The main criteria of evaluation will be the VES score at 6 months compared to baseline in
      both groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">November 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation Vitiligo</measure>
    <time_frame>At Baseline and at 6 weeks</time_frame>
    <description>Change from Baseline VES (Vitiligo Extend Score) at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life of patient</measure>
    <time_frame>At Baseline and at 6 weeks</time_frame>
    <description>Change from baseline DLQI at 6 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Vitiligo activity score</measure>
    <time_frame>At baseline and at 6 months</time_frame>
    <description>Change from vaseline SA-VES (self administrated VES) at 6 months</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glisodin tablet</intervention_name>
    <description>4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vitiligo

          -  Vitiligo, SOD, UVB

          -  Non-segmental vitiligo with BSA&gt;5%

        Exclusion Criteria:

          -  Criteria of non-inclusion

               -  Segmental or mixed vitiligo

               -  Pregnancy

               -  Vitiligo lesions localized only on hands and feet

               -  Immuno-suppressive drugs

               -  Corticosteroids

               -  Photosensitive drugs

               -  Photodermatosis

               -  Personal history of skin cancer

               -  Allergy to gluten
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Passeron Thierry, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Passeron Thierry, PhD</last_name>
    <phone>+33492034688</phone>
    <email>passeron.t@ch-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Glenet St√©phane, Ph</last_name>
    <phone>+33492039220</phone>
    <email>glenet.s@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Passeron</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritime</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Passeron Thierry, PhD</last_name>
      <phone>+33492034688</phone>
      <email>passeron.t@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Passeron Thierry, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

